{
    "title": "In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease.",
    "abst": "The in vivo characterization of a dual adenosine A(2A)/A(1) receptor antagonist in several animal models of Parkinson's disease is described. Discovery and scale-up syntheses of compound 1 are described in detail, highlighting optimization steps that increased the overall yield of 1 from 10.0% to 30.5%. Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",
    "title_plus_abst": "In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease. The in vivo characterization of a dual adenosine A(2A)/A(1) receptor antagonist in several animal models of Parkinson's disease is described. Discovery and scale-up syntheses of compound 1 are described in detail, highlighting optimization steps that increased the overall yield of 1 from 10.0% to 30.5%. Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",
    "pubmed_id": "20973483",
    "entities": [
        [
            35,
            71,
            "adenosine A2A/A1 receptor antagonist",
            "Chemical",
            "D058915"
        ],
        [
            92,
            111,
            "Parkinson's disease",
            "Disease",
            "D010300"
        ],
        [
            152,
            192,
            "adenosine A(2A)/A(1) receptor antagonist",
            "Chemical",
            "D058915"
        ],
        [
            221,
            240,
            "Parkinson's disease",
            "Disease",
            "D010300"
        ],
        [
            616,
            635,
            "Parkinson's disease",
            "Disease",
            "D010300"
        ],
        [
            670,
            681,
            "haloperidol",
            "Chemical",
            "D006220"
        ],
        [
            690,
            699,
            "catalepsy",
            "Disease",
            "D002375"
        ],
        [
            716,
            725,
            "reserpine",
            "Chemical",
            "D012110"
        ],
        [
            734,
            742,
            "akinesia",
            "Disease",
            "D004409"
        ],
        [
            748,
            765,
            "6-hydroxydopamine",
            "Chemical",
            "D016627"
        ],
        [
            767,
            773,
            "6-OHDA",
            "Chemical",
            "D016627"
        ],
        [
            818,
            822,
            "MPTP",
            "Chemical",
            "D015632"
        ]
    ],
    "split_sentence": [
        "In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease.",
        "The in vivo characterization of a dual adenosine A(2A)/A(1) receptor antagonist in several animal models of Parkinson's disease is described.",
        "Discovery and scale-up syntheses of compound 1 are described in detail, highlighting optimization steps that increased the overall yield of 1 from 10.0% to 30.5%.",
        "Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model."
    ],
    "if_txt_length_is_changed_flag": 0,
    "lines": [
        "D058915\tChemical\tadenosine A2A/A1 receptor antagonist\tIn vivo characterization of a dual <target> adenosine A2A/A1 receptor antagonist </target> in animal models of Parkinson 's disease .",
        "D010300\tDisease\tParkinson's disease\tIn vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of <target> Parkinson 's disease </target> .",
        "D058915\tChemical\tadenosine A(2A)/A(1) receptor antagonist\tThe in vivo characterization of a dual <target> adenosine A(2A)/A(1 ) receptor antagonist </target> in several animal models of Parkinson 's disease is described .",
        "D010300\tDisease\tParkinson's disease\tThe in vivo characterization of a dual adenosine A(2A)/A(1 ) receptor antagonist in several animal models of <target> Parkinson 's disease </target> is described .",
        "D010300\tDisease\tParkinson's disease\tCompound 1 is a potent A(2A)/A(1 ) receptor antagonist in vitro ( A(2A ) K(i ) = 4.1 nM ; A(1 ) K(i ) = 17.0 nM ) that has excellent activity , after oral administration , across a number of animal models of <target> Parkinson 's disease </target> including mouse and rat models of haloperidol-induced catalepsy , mouse model of reserpine-induced akinesia , rat 6-hydroxydopamine ( 6-OHDA ) lesion model of drug-induced rotation , and MPTP-treated non-human primate model .",
        "D006220\tChemical\thaloperidol\tCompound 1 is a potent A(2A)/A(1 ) receptor antagonist in vitro ( A(2A ) K(i ) = 4.1 nM ; A(1 ) K(i ) = 17.0 nM ) that has excellent activity , after oral administration , across a number of animal models of Parkinson 's disease including mouse and rat models of <target> haloperidol </target> -induced catalepsy , mouse model of reserpine-induced akinesia , rat 6-hydroxydopamine ( 6-OHDA ) lesion model of drug-induced rotation , and MPTP-treated non-human primate model .",
        "D002375\tDisease\tcatalepsy\tCompound 1 is a potent A(2A)/A(1 ) receptor antagonist in vitro ( A(2A ) K(i ) = 4.1 nM ; A(1 ) K(i ) = 17.0 nM ) that has excellent activity , after oral administration , across a number of animal models of Parkinson 's disease including mouse and rat models of haloperidol-induced <target> catalepsy </target> , mouse model of reserpine-induced akinesia , rat 6-hydroxydopamine ( 6-OHDA ) lesion model of drug-induced rotation , and MPTP-treated non-human primate model .",
        "D012110\tChemical\treserpine\tCompound 1 is a potent A(2A)/A(1 ) receptor antagonist in vitro ( A(2A ) K(i ) = 4.1 nM ; A(1 ) K(i ) = 17.0 nM ) that has excellent activity , after oral administration , across a number of animal models of Parkinson 's disease including mouse and rat models of haloperidol-induced catalepsy , mouse model of <target> reserpine </target> -induced akinesia , rat 6-hydroxydopamine ( 6-OHDA ) lesion model of drug-induced rotation , and MPTP-treated non-human primate model .",
        "D004409\tDisease\takinesia\tCompound 1 is a potent A(2A)/A(1 ) receptor antagonist in vitro ( A(2A ) K(i ) = 4.1 nM ; A(1 ) K(i ) = 17.0 nM ) that has excellent activity , after oral administration , across a number of animal models of Parkinson 's disease including mouse and rat models of haloperidol-induced catalepsy , mouse model of reserpine-induced <target> akinesia </target> , rat 6-hydroxydopamine ( 6-OHDA ) lesion model of drug-induced rotation , and MPTP-treated non-human primate model .",
        "D016627\tChemical\t6-hydroxydopamine\tCompound 1 is a potent A(2A)/A(1 ) receptor antagonist in vitro ( A(2A ) K(i ) = 4.1 nM ; A(1 ) K(i ) = 17.0 nM ) that has excellent activity , after oral administration , across a number of animal models of Parkinson 's disease including mouse and rat models of haloperidol-induced catalepsy , mouse model of reserpine-induced akinesia , rat <target> 6-hydroxydopamine </target> ( 6-OHDA ) lesion model of drug-induced rotation , and MPTP-treated non-human primate model .",
        "D016627\tChemical\t6-OHDA\tCompound 1 is a potent A(2A)/A(1 ) receptor antagonist in vitro ( A(2A ) K(i ) = 4.1 nM ; A(1 ) K(i ) = 17.0 nM ) that has excellent activity , after oral administration , across a number of animal models of Parkinson 's disease including mouse and rat models of haloperidol-induced catalepsy , mouse model of reserpine-induced akinesia , rat 6-hydroxydopamine ( <target> 6-OHDA </target> ) lesion model of drug-induced rotation , and MPTP-treated non-human primate model .",
        "D015632\tChemical\tMPTP\tCompound 1 is a potent A(2A)/A(1 ) receptor antagonist in vitro ( A(2A ) K(i ) = 4.1 nM ; A(1 ) K(i ) = 17.0 nM ) that has excellent activity , after oral administration , across a number of animal models of Parkinson 's disease including mouse and rat models of haloperidol-induced catalepsy , mouse model of reserpine-induced akinesia , rat 6-hydroxydopamine ( 6-OHDA ) lesion model of drug-induced rotation , and <target> MPTP </target> -treated non-human primate model ."
    ],
    "lines_lemma": [
        "D058915\tChemical\tadenosine A2A/A1 receptor antagonist\tin vivo characterization of a dual <target> adenosine a2a/a1 receptor antagonist </target> in animal model of Parkinson 's disease .",
        "D010300\tDisease\tParkinson's disease\tin vivo characterization of a dual adenosine a2a/a1 receptor antagonist in animal model of <target> Parkinson 's disease </target> .",
        "D058915\tChemical\tadenosine A(2A)/A(1) receptor antagonist\tthe in vivo characterization of a dual <target> adenosine a(2a)/a(1 ) receptor antagonist </target> in several animal model of Parkinson 's disease be describe .",
        "D010300\tDisease\tParkinson's disease\tthe in vivo characterization of a dual adenosine a(2a)/a(1 ) receptor antagonist in several animal model of <target> Parkinson 's disease </target> be describe .",
        "D010300\tDisease\tParkinson's disease\tcompound 1 be a potent a(2a)/a(1 ) receptor antagonist in vitro ( a(2a ) k(i ) = 4.1 nm ; a(1 ) k(i ) = 17.0 nm ) that have excellent activity , after oral administration , across a number of animal model of <target> Parkinson 's disease </target> include mouse and rat model of haloperidol-induced catalepsy , mouse model of reserpine-induced akinesia , rat 6-hydroxydopamine ( 6-ohda ) lesion model of drug-induced rotation , and mptp-treated non-human primate model .",
        "D006220\tChemical\thaloperidol\tcompound 1 be a potent a(2a)/a(1 ) receptor antagonist in vitro ( a(2a ) k(i ) = 4.1 nm ; a(1 ) k(i ) = 17.0 nm ) that have excellent activity , after oral administration , across a number of animal model of Parkinson 's disease include mouse and rat model of <target> haloperidol </target> -induced catalepsy , mouse model of reserpine-induced akinesia , rat 6-hydroxydopamine ( 6-ohda ) lesion model of drug-induced rotation , and mptp-treated non-human primate model .",
        "D002375\tDisease\tcatalepsy\tcompound 1 be a potent a(2a)/a(1 ) receptor antagonist in vitro ( a(2a ) k(i ) = 4.1 nm ; a(1 ) k(i ) = 17.0 nm ) that have excellent activity , after oral administration , across a number of animal model of Parkinson 's disease include mouse and rat model of haloperidol-induced <target> catalepsy </target> , mouse model of reserpine-induced akinesia , rat 6-hydroxydopamine ( 6-ohda ) lesion model of drug-induced rotation , and mptp-treated non-human primate model .",
        "D012110\tChemical\treserpine\tcompound 1 be a potent a(2a)/a(1 ) receptor antagonist in vitro ( a(2a ) k(i ) = 4.1 nm ; a(1 ) k(i ) = 17.0 nm ) that have excellent activity , after oral administration , across a number of animal model of Parkinson 's disease include mouse and rat model of haloperidol-induced catalepsy , mouse model of <target> reserpine </target> -induced akinesia , rat 6-hydroxydopamine ( 6-ohda ) lesion model of drug-induced rotation , and mptp-treated non-human primate model .",
        "D004409\tDisease\takinesia\tcompound 1 be a potent a(2a)/a(1 ) receptor antagonist in vitro ( a(2a ) k(i ) = 4.1 nm ; a(1 ) k(i ) = 17.0 nm ) that have excellent activity , after oral administration , across a number of animal model of Parkinson 's disease include mouse and rat model of haloperidol-induced catalepsy , mouse model of reserpine-induced <target> akinesia </target> , rat 6-hydroxydopamine ( 6-ohda ) lesion model of drug-induced rotation , and mptp-treated non-human primate model .",
        "D016627\tChemical\t6-hydroxydopamine\tcompound 1 be a potent a(2a)/a(1 ) receptor antagonist in vitro ( a(2a ) k(i ) = 4.1 nm ; a(1 ) k(i ) = 17.0 nm ) that have excellent activity , after oral administration , across a number of animal model of Parkinson 's disease include mouse and rat model of haloperidol-induced catalepsy , mouse model of reserpine-induced akinesia , rat <target> 6-hydroxydopamine </target> ( 6-ohda ) lesion model of drug-induced rotation , and mptp-treated non-human primate model .",
        "D016627\tChemical\t6-OHDA\tcompound 1 be a potent a(2a)/a(1 ) receptor antagonist in vitro ( a(2a ) k(i ) = 4.1 nm ; a(1 ) k(i ) = 17.0 nm ) that have excellent activity , after oral administration , across a number of animal model of Parkinson 's disease include mouse and rat model of haloperidol-induced catalepsy , mouse model of reserpine-induced akinesia , rat 6-hydroxydopamine ( <target> 6-ohda </target> ) lesion model of drug-induced rotation , and mptp-treated non-human primate model .",
        "D015632\tChemical\tMPTP\tcompound 1 be a potent a(2a)/a(1 ) receptor antagonist in vitro ( a(2a ) k(i ) = 4.1 nm ; a(1 ) k(i ) = 17.0 nm ) that have excellent activity , after oral administration , across a number of animal model of Parkinson 's disease include mouse and rat model of haloperidol-induced catalepsy , mouse model of reserpine-induced akinesia , rat 6-hydroxydopamine ( 6-ohda ) lesion model of drug-induced rotation , and <target> mptp </target> -treated non-human primate model ."
    ]
}